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Edited by Masayuki MiyasakaAbstract Dilated cardiomyopathy often results from autoim-
munity triggered by microbial infections during myocarditis.
However, it remains unclear how immunological disorders are
implicated in pathogenesis of autoimmune myocarditis. Here,
we demonstrated that Sema4A, a class IV semaphorin, plays
key roles in experimental autoimmune myocarditis (EAM). Den-
dritic cells pulsed with myosin heavy chain-a peptides induced se-
vere myocarditis in wild-type mice, but not in Sema4A-deﬁcient
mice. In adoptive transfer experiments, CD4+ T-cells from wild-
type mice induced severe myocarditis, while CD4+ T-cells from
Sema4A-deﬁcient mice exhibited considerably attenuated myo-
carditis. Our results indicated that Sema4A is critically involved
in EAM by regulating diﬀerentiation of T-cells.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Myocarditis is an inﬂammatory heart disease that can be ini-
tiated by infectious pathogens, which is a frequent cause of
cardiac disease among young adults. Myocarditis often results
from infections with enteroviruses such as coxsackievirus B3 or
adenoviruses [1]. In addition, cardiotropic bacteria such asAbbreviations:DCM, dilated cardiomyopathy; SCID, severe combined
immunodeﬁciency; EAM, experimental autoimmune myocarditis;
MyHC-a, myosin a heavy chain; DCs, dendritic cells; IFN-c,
Interferon-c; TH1, type 1 helper T-cells; IL, interleukin; Tim-2, T-
cell, immunoglobulin and mucin domain protein 2; EAE, experimental
autoimmune encephalomyelitis; Treg, regulatory T-cells; Foxp3, fork-
head box P3
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doi:10.1016/j.febslet.2008.10.040Borrelia and Chlamydia can induce myocarditis and heart fail-
ure. Cumulative evidence suggests that myocarditis is a precur-
sor of dilated cardiomyopathy (DCM), the major cause of
heart failure and heart transplantation [1]. It has been sug-
gested that autoimmune responses to cardiac antigens that
are exposed after heart damage play a crucial role in prolonged
damage of the myocardium, which promotes the development
of DCM [2]. In fact, many aﬀected individuals develop heart
antigen-speciﬁc autoantibody responses and immunosuppres-
sive therapy can improve heart function in DCM patients
who have no evidence of viral or bacterial genomes in heart
biopsies. In addition, peripheral blood lymphocytes from
DCM patients can adoptively transfer the disease to severe
combined immunodeﬁciency (SCID) mice lacking T- and B-
cells [3]. Collectively, these ﬁndings strongly suggest that
post-infectious autoimmunity is involved in DCM develop-
ment. However, it has not been fully elucidated how patho-
genic autoimmunity is triggered in myocarditis, making it
diﬃcult to treat myocarditis by immunosuppression.
Experimental autoimmune myocarditis (EAM) is a model of
post-infectious myocarditis. EAM can be induced in suscepti-
ble mouse strains by immunizing with self-peptides derived
from the myosin a heavy chain (MyHC-a) together with a
strong adjuvant [4], or by injecting MyHC-a-loaded dendritic
cells (DCs) [5]. Collectively, these ﬁndings imply that immune
tolerance is broken by damage during infection, resulting in
the release of self-antigens, the activation of DCs, and the sub-
sequent activation of autoreactive T-cells. Consistent with this
hypothesis, it has been demonstrated that EAM is a T-cell
mediated autoimmune disease that can be transferred by
CD4+ T-cells from EAM mice [5]. Traditionally, CD4+ T-cells
have been divided into two subsets, Interferon-c (IFN-c)-pro-
ducing type 1 helper T-cells (TH1) and interleukin (IL)-4-, IL-
10-, and IL-13-producing TH2 cells. It has been assumed that
the TH1/ TH2 cytokine balance is important in the develop-
ment of myocarditis [6]. Recently, this model has been chal-
lenged by the identiﬁcation of the IL-17-producing TH17 cell
subset, which has been shown to be involved in various models
of immune-mediated tissue injury [7]. In addition, it has been
reported that immuno-regulatory cytokines such as IL-10blished by Elsevier B.V. All rights reserved.
3936 N. Makino et al. / FEBS Letters 582 (2008) 3935–3940[8,9] and IL-13 [10] can ameliorate EAM development. In this
context, the precise mechanism of CD4+ T-cells in the develop-
ment of EAM remains unclear.
Semaphorins were originally identiﬁed as axon guidance fac-
tors during neuronal development [11]. In recent years, sem-
aphorins have emerged as important factors that have
diverse and critical functions in other physiological processes,
including heart morphogenesis, vascular growth, tumor pro-
gression, and immune cell regulation. In particular, cumulative
evidence indicates that semaphorins are crucially involved in
various phases of the immune response [12,13]. The class IV
semaphorin subfamily member, Sema4A, regulates T-cell–
mediated immune responses by interacting with its receptor
Tim-2 (T-cell, immunoglobulin and mucin domain protein 2)
which is expressed on TH2 cells as a negative regulator [14–
16]. Sema4A expression is speciﬁcally induced on the cell sur-
face of TH1 cells during helper T-cell diﬀerentiation. We previ-
ously reported that T-cell derived Sema4A is necessary for
regulating T-cell diﬀerentiation. In fact, Sema4A-deﬁcient mice
have impaired TH1-responses but rather enhanced TH2-re-
sponses. Furthermore, anti-Sema4A antibody treatment atten-
uated the development of experimental autoimmuneFig. 1. Sema4A-deﬁcient mice were resistant to EAM. (A) Autoimmune my
DCs. Severe myocarditis was observed in wild-type mice (left), while Sema4
mice were resistant to EAM. Disease severity scores of individual wild-type (o
activated, MyHC-a loaded DCs. (C) The number of heart-inﬁltrating inﬂam
(upper). Heart-inﬁltrating cells were isolated from the hearts of wild-type (l
activated, MyHC-a loaded DCs. Cells were analyzed by ﬂow cytometry, and a
leukocytes (lower). The cellular composition of the heart inﬁltrate in immun
results are representative of ﬁve independent experiments.encephalomyelitis (EAE), which is a T-cell mediated disease.
In this context, Sema4A is potentially a strong therapeutic tar-
get for T-cell mediated diseases.
In this study, we show that Sema4A-deﬁcient mice are resis-
tant to the development of EAM, and that a disregulated bal-
ance of helper T-cells is responsible for this resistance. Our
ﬁndings suggest that Sema4A is a potential therapeutic target
for autoimmune myocarditis.2. Materials and methods
2.1. Mice
BALB/c and SCID mice were purchased from Nippon Clea (Japan).
BALB/c Sema4A-deﬁcient mice were generated as described previously
[14]. Six- to ten-week-old mice were used for all experiments. Mice
were maintained in a speciﬁc pathogen free environment. All experi-
mental procedures complied with our institutional guidelines.
2.2. Induction of autoimmune myocarditis
Immature bone marrow-derived DCs were generated as described
previously [17]. Immature DCs were pulsed overnight with 10 lg/ml
of mouse MyHC-a (amino acids 614–629) (Ac-RSLKLMATLF-
STYASADR-OH; purity >95%; Biologica, Japan). Bold letters indi-ocarditis was induced by immunizing with activated, MyHC-a loaded
A-deﬁcient mice were resistant to EAM (right). (B) Sema4A-deﬁcient
pen circles) and Sema4A-deﬁcient (closed circles) mice immunized with
matory cells was decreased in EAM-induced in Sema4A-deﬁcient mice
eft) or Sema4A-deﬁcient (right) mice 10 days after immunization with
CD45/side scatter plot was used to determine the percentage of CD45+
ized wild-type (white bars) or Sema4A-deﬁcient (black bars) mice. The
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tide to increase solubility [18]. DCs were treated with LPS (1 lg/ml,
Escherichia coli 0111:B4; Sigma) and an anti-CD40 antibody (5 lg/
ml, clone 3/23, BD PharMingen, USA) for 4 h. DCs were intraperito-
neally injected into wild-type or Sema4A-deﬁcient mice (1 · 105 cells/
mouse) on days 0, 2 and 4.
2.3. Histopathology
On day 10, mice were killed and their hearts were removed, ﬁxed in
10% neutral buﬀered formalin, and processed for hematoxylin and eo-
sin staining. Myocarditis was scored on a scale from 0 to 4 (0, no inﬁl-
tration of inﬂammatory cells; 1, small foci of inﬂammatory cells
between myocytes; 2, larger foci of >100 inﬂammatory cells; 3, >10%
of a cross section has inﬂammation; 4, >30% of a cross section has
inﬂammation).
2.4. In vitro restimulation of CD4+ T-cells
CD4+ T-cells were puriﬁed from spleens using an automated mag-
netic cell sorter (Auto MACS, Miltenyi Biotech, Germany) with
>95% purity in all experiments. These cells (1 · 105) were stimulated
for 48 h with MyHC-a peptides in the presence of irradiated (3000
cGy) splenocytes (5 · 105) from wild-type littermates. Cytokine levels0
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Fig. 2. CD4+ T-cells from Sema4A-deﬁcient mice produced high amounts
immunized wild-type versus Sema4A-deﬁcient mice. CD4+ T-cells isolated fro
mice (black bars) were restimulated with a MyHC-a peptide. The cytokine lev
restimulation. Error bars indicate means ± S.D. ****, P < 0.001; each value
spleens of immunized wild-type or Sema4A-deﬁcient mice were analyzed by in
mice. CD25+CD4+ T-cells from wild-type (open circles) or Sema4A-deﬁcien
cells in the presence of irradiated APCs and anti-CD3 for 3 days. Incorporatio
the culture was measured. Error bars indicate means ± S.D.in the culture supernatants were measured using ELISA kits (R&D
Biosystems, USA) or the Bio-Plex suspension array system (BIO-
RAD, USA). For proliferation assays, cells were pulsed with 2 lCi
[3H] thymidine for the last 12 h of culture.
2.5. In vitro Treg assays
CD25+CD4+ T-cells from wild-type or Sema4A-deﬁcient mice were
co-cultured with syngeneic CD25CD4+T-cells (2 · 104) in the pres-
ence of irradiated (2000 cGy) APCs (5 · 104) and anti-CD3 (10 lg/
ml, clone 145-2C11, eBioscience, USA) for 3 days in 96-well round-
bottomed plates. Incorporation of [3H] thymidine by proliferating lym-
phocytes during the last 14 h of the culture was measured.
2.6. Isolation of heart-inﬁltrating cells
Heart-inﬁltrating cells were isolated as described previously [19]. The
heart was cannulated with a 22-gauge needle from the apex to the left
ventricle after binding the ascending aorta. The heart was perfused at a
constant ﬂow of 1.1 ml/min for 3 min with a Ca2+-free bicarbonate-
based buﬀer as described previously [19]. Enzymatic digestion was ini-
tiated by perfusing with the above solution containing collagenase D
(0.895 mg/ml, Roche, Switzerland) and protease type XIV (0.5 mg/
ml, Sigma) for an additional 7 min. The heart was placed into a PetriN-γ IL-17
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of IL-4 and IL-10. (A) CD4+ T-cell cytokine production patterns of
m the spleens of immunized wild-type (white bars) or Sema4A-deﬁcient
els in the culture supernatants were measured by Bio-Plex after 48 h of
was analyzed by a student t-test. (B) CD4+ T-cells isolated from the
tracellular staining. (C) Normal activities of Treg in Sema4A-deﬁcient
t (closed circles) mice were co-cultured with syngeneic CD25CD4+T-
n of [3H] thymidine by proliferating lymphocytes during the last 14 h of
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sodium azide in phosphate-buﬀered saline) and manually dispersed
into a single cell suspension using razor blades. Single cell suspensions
were sequentially ﬁltered through 100-lm and 40-lm cell strainers (BD
Falcon, USA) and ﬁnally through 20-lm self-assembled strainers
(Millipore, USA).
2.7. Adoptive T-cell transfers
Spleen cells from EAM mice were cultured for 72 h on MyHC-a
(10 lg/ml)-pulsed irradiated splenocytes in the presence of an anti-
CD28 monoclonal antibody (5 lg/ml clone 37.51 BD Pharmingen).
CD4+ T-cells were negatively sorted by autoMACS and transferred
into recipient SCID mice (1 · 106 cells/mouse). Ten days after CD4+
T-cell transfer, myocarditis was scored as described above.
2.8. Flow cytometry
Cells were stained with the following antibodies: anti-CD45 (Ly-5),
anti-CD3 (145-2C11), anti-Gr-1 (RB6-8C5), anti-CD11b (M1/70) con-
jugated with FITC, phycoerythrin (PE) in the presence of Fc block
(anti-CD16/32, 2.4G2). Analysis of intracellular forkhead box P3
(Foxp3) was performed according to the manufacturers protocol
(eBioscience). All antibodies were from eBiosciences, except for the
anti-CD11b, which was purchased from BD Pharmingen.3. Results and discussion
3.1. Sema4A-deﬁcient mice were resistant to EAM
We previously found that Sema4A is crucial for the diﬀeren-
tiation of CD4+ T-cells [14]. To investigate the pathogenic rel-
evance of Sema4A in the development of EAM, we injected
MyHC-a-loaded DCs into Sema4A-deﬁcient or wild-type mice
and examined their hearts for inﬂammation. Wild-type mice
exhibited strong cardiac inﬂammatory disease with a signiﬁ-
cant inﬁltration of inﬂammatory mononuclear cells
(Fig. 1A). The hearts from wild-type mice were macroscopi-
cally enlarged (data not shown). In contrast, Sema4A-deﬁcient
mice showed a very mild phenotype (Fig. 1A and B). Consis-Fig. 3. CD4+ T-cells from immunized Sema4A-deﬁcient mice could not indu
deﬁcient mice were restimulated in vitro for 72 h with MyHC-a peptides an
injected intraperitoneally into recipient SCID mice. CD4+ T-cells from imm
induced autoimmune myocarditis. (B) Disease severity scores of individual
wild-type (open circles) or Sema4A-deﬁcient (closed circles) mice.tent with the diﬀerence in the severities of EAM, the total num-
ber of inﬁltrating CD45+ inﬂammatory cells was signiﬁcantly
decreased in Sema4A-deﬁcient mice compared to wild-type
mice (Fig. 1C). In addition, the proportions of inﬁltrating mac-
rophages and granulocytes among inﬁltrating inﬂammatory
cells in Sema4A-deﬁcient mice were much lower than those
in wild-type mice (Fig. 1C). Collectively, these ﬁndings
strongly suggest that Sema4A is pathologically important for
the development of EAM.
3.2. CD4+ T-cells from Sema4A-deﬁcient mice produced high
amounts of IL-4 and IL-10
Sema4A plays a key role in diﬀerentiation of CD4+ T-cells
[14]. To investigate the relevance of Sema4A in T-cell activa-
tion in EAM, we performed T-cell recall assays. Consistent
with previous ﬁndings on Sema4A-deﬁcient mice [14],
MyHC-a-speciﬁc T-cells showed signiﬁcantly enhanced IL-4
and IL-10 production (Fig. 2A). Although it has been reported
that IL-17 is involved in the development of EAM [20–22], IL-
17 production by Sema4A-deﬁcient T-cells was only slightly
enhanced. In addition, in vitro TH17 polarization of naı¨ve Se-
ma4A-deﬁcient CD4+ T-cells was not impaired (Supplementary
Fig. 1A). These ﬁndings suggested that TH17 was not involved
in the resistance to EAM in Sema4A-deﬁcient mice. To deter-
mine the involvement of regulatory T-cells (Treg), we per-
formed intracellular Foxp3 staining of CD4+ T-cells isolated
from the spleens of EAM-induced mice. The proportion of
Foxp3+ Treg cells isolated from Sema4A-deﬁcient mice was
comparable to those from wild-type mice (Fig. 2B). Consistent
with this ﬁnding, the suppressive activities of CD25+CD4+ T-
cells were not aﬀected in Sema4A-deﬁcient mice (Fig. 2C)
showing that Treg is not involved in the phenotype of Se-
ma4A-deﬁcient mice.
We have previously reported that Sema4A-deﬁcient mice
exhibited defective in vivo TH1-responses but rather enhancedce myocarditis. (A) Splenocytes from immunized wild-type or Sema4A-
d anti-CD28 antibodies. The resulting CD4+ T-cells were puriﬁed and
unized wild-type mice (upper) but not Sema4A-deﬁcient mice (lower)
SCID mice with adoptively transferred CD4+ T-cells from immunized
N. Makino et al. / FEBS Letters 582 (2008) 3935–3940 3939in vivo TH2-responses [14]. Also in the case of the genetic de-
fects in a Sema4A-receptor, Tim-2-deﬁcient mice show exacer-
bated lung inﬂammation accompanied by enhanced TH2-
responses [23]. Consistent with this ﬁnding, we found that
CD4+ T-cells from Sema4A-deﬁcient mice immunized with
MyHC-a exhibited enhanced production of TH2 cytokines,
such as IL-4 and IL-10. In this context, the TH2 bias in Se-
ma4A-deﬁcient mice seems to contribute to EAM resistance,
although further studies would be required to determine how
TH2 cytokines are involved in this phenotype.
3.3. Abnormal CD4+ T-cells were responsible for the resistance
to myocarditis in Sema4A-deﬁcient mice
To determine whether the abnormal diﬀerentiation of helper
T-cells was responsible for the resistance to myocarditis in Se-
ma4A-deﬁcient mice, we isolated splenic T-cells from mice that
had been immunized with DCs, stimulated these T-cells with
MyHC-a presented by syngeneic antigen-presenting cells,
and adoptively transferred these T-cells into SCID mice. As
shown in Fig. 3A, wild-type CD4+ T-cells induced severe myo-
carditis. In contrast, Sema4A-deﬁcient CD4+ T-cells did not
induce myocarditis (Fig. 3B). However, Sema4A-deﬁcient
CD4+ T-cells proliferated in response to MyHC-a-peptides
to the same extent as wild-type CD4+ T-cells (Supplementary
Fig. 1B). Taken together, our results indicate that abnormal
CD4+ T-cell diﬀerentiation was primarily responsible for the
resistance to EAM in Sema4A-deﬁcient mice.
In summary, we demonstrated that Sema4A-deﬁcient mice
were resistant to the initiation of EAM, in which increased
TH2 cytokines production by Sema4A-deﬁcient CD4
+ T-cells
seems to be important for this resistance. Our ﬁndings suggest
that Sema4A is critically involved in the development of myo-
carditis and dilated cardiomyopathy.
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